Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34495281.
- Also identified by DOI 10.1001/jamadermatol.2021.3450 and PMC identifier 8427493.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case series study uses data from the FDA Adverse Event Reporting System to investigate a potential association between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.
Medical subject headings
- Stevens-Johnson Syndrome